Abstract

Ehab Jasim Mohammad, Waleed Nassar Jaffal, Kanaan Mahdi Abbas

Objective: To assess the welfare and efficiency of combined cabergoline and tadalafil in the treatment of patients with psychogenic erectile dysfunction.
Patients and methods:
From January 2015 to January 2020, and 580 patients with psychogenic erectile dysfuction presented at Al Ramadi and Al Yarmouk teaching hospitals and private clinics were enrolled in this prospective case control study. The age of patients ranged from 20 to 62 years. Thirty patients were lost the follow up and did not complete the study. The patients randomly divided into 2 groups; A and B, group A consisting of 250 patients, received tadalafil tablets 5 mg daily alone for 1 month and group B consisting of 300 patients received cabergoline 0.5 mg weekly in addition to tadalafil 5 mg daily, and we compared the improvement in the erectile function among the 2 groups.
Results: There was no statistically significant difference in age between the 2 groups (p value > 0.05). There was statistically significant improvement in the erectile function in patients taking cabergoline and tadalafil compared to tadalafil monotherapy (p value < 0.05 ).
Conclusion: The use of combination treatment of cabercoline and tadalafil was unscathed and more operative in the treating of patients with psychogenic dysfunction erectile compared to tadalafil monotherapy.